Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jonathan M. DeLiberty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6001-6678; OpenAlex author ID A5023816378. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 6

  1. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.28.734981↗
  2. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.01.756025↗
  3. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  4. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  5. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  6. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Clint A. Stalnecker · 5 shared papers, 2021–2026 · strength 0.88
  2. Kirsten L. Bryant · 5 shared papers, 2020–2026 · strength 0.75
  3. Mariaelena Pierobon · 4 shared papers, 2020–2026 · strength 0.56
  4. Adrienne D. Cox · 4 shared papers, 2020–2025 · strength 0.49
  5. Channing J. Der · 4 shared papers, 2020–2025 · strength 0.49
  6. Ryan N. Robb · 2 shared papers, 2025–2026 · strength 0.45
  7. Mallory K. Roach · 2 shared papers, 2025–2026 · strength 0.45
  8. Bjoern Papke · 3 shared papers, 2020–2022 · strength 0.30
  9. Emanuel F. Petricoin · 3 shared papers, 2020–2022 · strength 0.30
  10. Craig M. Goodwin · 3 shared papers, 2020–2022 · strength 0.30
  11. Kristina Drizyte‐Miller · 2 shared papers, 2021–2025 · strength 0.28
  12. Andrew J. Aguirre · 2 shared papers, 2020–2026 · strength 0.28
  13. Timothy Paul Heffernan · 1 shared paper, 2026 · strength 0.21
  14. Joao A Paulo · 1 shared paper, 2026 · strength 0.21
  15. Tobiloba E. Oni · 1 shared paper, 2026 · strength 0.21
  16. Brendan D. Parent · 1 shared paper, 2026 · strength 0.21
  17. Joseph Douglas Mancias · 1 shared paper, 2026 · strength 0.21
  18. John P. Morris · 1 shared paper, 2025 · strength 0.19
  19. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.19
  20. Sarah E. Ackermann · 1 shared paper, 2025 · strength 0.19
  21. J. Nathaniel Diehl · 2 shared papers, 2020–2021 · strength 0.17
  22. Jennifer E. Klomp · 2 shared papers, 2020–2021 · strength 0.17
  23. Andrew M. Waters · 2 shared papers, 2020–2021 · strength 0.17
  24. A. Cole Edwards · 1 shared paper, 2022 · strength 0.13
  25. Michael F. Coleman · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.